446 related articles for article (PubMed ID: 29961079)
21. [Clinicopathological features and prognostic analysis of patients with signet ring cell gastric carcinoma].
Cui J; Liang H; Deng J; Ding X; Wang X; Zhang L; Liang Y; Jiang N
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):367-70. PubMed ID: 26463028
[TBL] [Abstract][Full Text] [Related]
22. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
Kim H; Kim BH; Lee D; Shin E
Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy
Li Y; Ma FH; Xue LY; Tian YT
World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
[TBL] [Abstract][Full Text] [Related]
24. Deficiency of mismatch repair genes is less frequently observed in signet ring cell compared with non-signet ring cell gastric cancer.
Hirotsu Y; Mochizuki H; Amemiya K; Ohyama H; Yoshimura D; Amano H; Miura Y; Ashizawa H; Nakagomi K; Takaoka S; Hosoda K; Suzuki Y; Oyama T; Hada M; Kojima Y; Omata M
Med Oncol; 2019 Jan; 36(3):23. PubMed ID: 30694393
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: A Surveillance, Epidemiology, and End Results database analysis.
Shi T; Huang M; Han D; Tang X; Chen Y; Li Z; Liu C; Xiang D; Wang T; Chen Y; Wang R; Lei Z; Chu X
Cancer Med; 2019 Apr; 8(4):1930-1940. PubMed ID: 30864303
[TBL] [Abstract][Full Text] [Related]
26. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor.
Hugen N; Verhoeven RH; Lemmens VE; van Aart CJ; Elferink MA; Radema SA; Nagtegaal ID; de Wilt JH
Int J Cancer; 2015 Jan; 136(2):333-9. PubMed ID: 24841868
[TBL] [Abstract][Full Text] [Related]
27. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen.
Bozkaya Y; Erdem GU; Özdemir NY; Hocazade C; Yazici O; Demirci NS; Zengin N
J Cancer Res Ther; 2018 Sep; 14(Supplement):S742-S747. PubMed ID: 30249897
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study.
Pozos-Ochoa LI; Lino-Silva LS; León-Takahashi AM; Salcedo-Hernández RA
Pathol Oncol Res; 2018 Jul; 24(3):609-616. PubMed ID: 28785968
[TBL] [Abstract][Full Text] [Related]
29. Proteomic Profiling of Gastric Signet Ring Cell Carcinoma Tissues Reveals Characteristic Changes of the Complement Cascade Pathway.
Fan Y; Bai B; Liang Y; Ren Y; Liu Y; Zhou F; Lou X; Zi J; Hou G; Chen F; Zhao Q; Liu S
Mol Cell Proteomics; 2021; 20():100068. PubMed ID: 33676000
[TBL] [Abstract][Full Text] [Related]
30. The differences in biological behavior and gene expression characteristics between pure and mixed early gastric signet ring cell carcinomas.
Wang X; Li X; Yang P; Qin X; Yu J; Cheng Y; Zhang G; Tang L
Dig Liver Dis; 2023 Jun; 55(6):815-822. PubMed ID: 36529637
[TBL] [Abstract][Full Text] [Related]
31. Deep learning-based AI model for signet-ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer.
Li C; Qin Y; Zhang WH; Jiang H; Song B; Bashir MR; Xu H; Duan T; Fang M; Zhong L; Meng L; Dong D; Hu Z; Tian J; Hu JK
Med Phys; 2022 Mar; 49(3):1535-1546. PubMed ID: 35032039
[TBL] [Abstract][Full Text] [Related]
32. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
Korphaisarn K; Morris V; Davis JS; Overman MJ; Fogelman DR; Kee BK; Dasari A; Raghav KPS; Shureiqi I; Trupti M; Wolff RA; Eng C; Menter DG; Hamilton S; Kopetz S
Br J Cancer; 2019 Sep; 121(6):505-510. PubMed ID: 31406299
[TBL] [Abstract][Full Text] [Related]
33. Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach.
Bozkaya Y; Erdem GU; Ozdemir NY; Demirci NS; Hocazade C; Yazıcı O; Zengin N
Curr Med Res Opin; 2017 Jan; 33(1):109-116. PubMed ID: 27646639
[TBL] [Abstract][Full Text] [Related]
34. Transcriptomic Profiling Reveals AKR1C1 and AKR1C3 Mediate Cisplatin Resistance in Signet Ring Cell Gastric Carcinoma via Autophagic Cell Death.
Phoo NLL; Dejkriengkraikul P; Khaw-On P; Yodkeeree S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830394
[TBL] [Abstract][Full Text] [Related]
35. Histopathologic Analysis of Signet-ring Cell Carcinoma In Situ in Patients With Hereditary Diffuse Gastric Cancer.
Tsugeno Y; Nakano K; Nakajima T; Namikawa K; Takamatsu M; Yamamoto N; Fujisaki J; Nunobe S; Kitagawa M; Takeuchi K; Kawachi H
Am J Surg Pathol; 2020 Sep; 44(9):1204-1212. PubMed ID: 32520759
[TBL] [Abstract][Full Text] [Related]
36. Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model.
Yamaguchi K; Yoshihiro T; Ariyama H; Ito M; Nakano M; Semba Y; Nogami J; Tsuchihashi K; Yamauchi T; Ueno S; Isobe T; Shindo K; Moriyama T; Ohuchida K; Nakamura M; Nagao Y; Ikeda T; Hashizume M; Konomi H; Torisu T; Kitazono T; Kanayama T; Tomita H; Oda Y; Kusaba H; Maeda T; Akashi K; Baba E
Gastric Cancer; 2022 Sep; 25(5):862-878. PubMed ID: 35661943
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Lymph Node Metastasis and Differences Between Pure and Mixed Histologic Types of Early Gastric Signet-ring Cell Carcinomas.
Chu Y; Mao T; Li X; Jing X; Ren M; Huang Z; Zhou XB; Chen Y; Tian Z
Am J Surg Pathol; 2020 Jul; 44(7):934-942. PubMed ID: 32149737
[TBL] [Abstract][Full Text] [Related]
38. TAZ is highly expressed in gastric signet ring cell carcinoma.
Yue G; Sun X; Gimenez-Capitan A; Shen J; Yu L; Teixido C; Guan W; Rosell R; Liu B; Wei J
Biomed Res Int; 2014; 2014():393064. PubMed ID: 24707483
[TBL] [Abstract][Full Text] [Related]
39. Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
Lemoine N; Adenis A; Bouche O; Duhamel A; Heurgue A; Leteurtre E; Amela E; Salleron J; Hebbar M
Anticancer Res; 2016 Oct; 36(10):5543-5549. PubMed ID: 27798928
[TBL] [Abstract][Full Text] [Related]
40. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
